Themis Medicare Ltd

Themis Medicare Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Themis Medicare Ltd

₹ 288 0.52%
21 Nov - close price
themismedicare.com BSE: 530199 NSE: THEMISMED
About

Themis Medicare is principally engaged in the activities pertaining to manufacturing of pharmaceutical products, especially in Formulation and API activity.[1]

Key Points

Business Segments[1]
A) Hospital Business - Critical Care Division, Intensive Care Division, Institution Business, Exports. Hospital Business is a major growth driver. Critical Care and Intensive Care teams contribute to building Hospital Business with new launches and increased hospital/doctor’s coverage.

Website BSE NSE
  • Market Cap ₹ 2,646 Cr.
  • Current Price ₹ 288
  • High / Low ₹ 317 / 154
  • Stock P/E 70.2
  • Book Value ₹ 35.3
  • Dividend Yield 0.17 %
  • ROCE 11.4 %
  • ROE 8.49 %
  • Face Value ₹ 1.00
Edit ratios

Pros

  • Company has reduced debt.

Cons

  • Stock is trading at 8.14 times its book value
  • Dividend payout has been low at 12.2% of profits over last 3 years
  • Company has high debtors of 170 days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln

Part of BSE Allcap BSE SmallCap BSE Healthcare

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024
107.39 94.92 79.80 94.44 91.00 88.78 80.10 69.32 104.78 82.51 75.52 106.08 99.59
83.93 77.62 65.38 74.07 69.65 73.51 69.61 57.88 92.37 74.44 67.04 76.83 82.57
Operating Profit 23.46 17.30 14.42 20.37 21.35 15.27 10.49 11.44 12.41 8.07 8.48 29.25 17.02
OPM % 21.85% 18.23% 18.07% 21.57% 23.46% 17.20% 13.10% 16.50% 11.84% 9.78% 11.23% 27.57% 17.09%
0.21 4.14 1.84 0.68 1.97 5.90 2.95 6.32 2.44 0.56 -0.25 -0.88 -0.55
Interest 2.05 2.13 1.93 2.26 2.37 2.23 2.71 1.76 2.04 2.68 1.68 1.44 1.60
Depreciation 2.38 2.37 2.39 2.46 2.56 2.67 2.80 1.05 3.07 3.10 0.99 1.01 1.06
Profit before tax 19.24 16.94 11.94 16.33 18.39 16.27 7.93 14.95 9.74 2.85 5.56 25.92 13.81
Tax % 21.47% 28.28% 36.77% 28.72% 26.37% 25.75% 23.83% 16.05% 27.10% 29.82% 44.60% 27.78% 28.53%
15.12 12.15 7.55 11.63 13.53 12.09 6.04 12.56 7.10 2.00 3.09 18.71 9.87
EPS in Rs 1.64 1.32 0.82 1.26 1.47 1.31 0.66 1.37 0.77 0.22 0.34 2.03 1.07
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 TTM
148 172 167 203 217 210 184 202 231 395 354 382 364
139 153 156 171 184 184 182 166 181 299 287 330 301
Operating Profit 9 19 11 31 33 26 3 36 50 96 67 52 63
OPM % 6% 11% 7% 15% 15% 12% 1% 18% 22% 24% 19% 14% 17%
3 4 12 3 3 3 3 3 4 7 12 5 -1
Interest 15 16 14 12 12 12 12 13 13 9 10 9 7
Depreciation 6 6 7 7 7 7 8 8 9 9 10 12 6
Profit before tax -9 1 2 15 16 9 -15 18 32 84 59 35 48
Tax % -5% -34% -30% -4% 10% 1% -13% 12% 17% 27% 26% 29%
-8 2 2 15 15 9 -13 16 27 62 43 25 34
EPS in Rs -1.01 0.18 0.24 1.77 1.64 1.01 -1.38 1.73 2.90 6.69 4.71 2.69 3.66
Dividend Payout % 0% 0% 0% 0% 0% 0% 0% 10% 15% 7% 11% 19%
Compounded Sales Growth
10 Years: 8%
5 Years: 16%
3 Years: 18%
TTM: 6%
Compounded Profit Growth
10 Years: 32%
5 Years: 32%
3 Years: -2%
TTM: 17%
Stock Price CAGR
10 Years: 33%
5 Years: 64%
3 Years: 47%
1 Year: 87%
Return on Equity
10 Years: 13%
5 Years: 16%
3 Years: 17%
Last Year: 8%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Sep 2024
Equity Capital 8 8 8 9 9 9 9 9 9 9 9 9 9
Reserves 36 40 40 56 133 147 134 150 177 234 273 292 316
124 115 109 95 82 80 82 100 87 80 92 96 44
58 67 67 61 54 56 74 67 65 61 82 93 146
Total Liabilities 225 231 225 220 278 292 299 326 338 384 456 490 515
94 91 92 89 124 126 123 116 133 144 162 168 75
CWIP 10 11 3 5 9 2 2 8 2 3 3 3 3
Investments 10 10 11 11 12 11 11 11 11 11 11 11 11
111 119 119 115 133 153 162 191 192 226 280 308 426
Total Assets 225 231 225 220 278 292 299 326 338 384 456 490 515

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
-3 8 11 19 -2 8 11 0 57 34 16 22
-1 -3 -2 -4 -4 -0 -4 -5 -16 -16 -24 -16
28 2 -15 -13 5 -9 -10 7 -26 -18 0 -9
Net Cash Flow 24 8 -6 2 -0 -1 -3 2 16 1 -8 -3

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 65 71 88 73 81 120 145 186 123 93 150 170
Inventory Days 237 231 223 210 250 253 284 313 273 150 213 188
Days Payable 247 250 272 152 163 156 186 171 144 79 123 126
Cash Conversion Cycle 55 52 38 131 168 217 243 328 253 165 239 233
Working Capital Days 77 63 68 53 74 132 134 178 154 125 177 181
ROCE % 4% 10% 10% 17% 15% 9% -1% 13% 17% 31% 20% 11%

Shareholding Pattern

Numbers in percentages

1 Recently
Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024
67.18% 67.18% 67.18% 67.17% 67.17% 67.16% 67.16% 67.16% 67.16% 67.15% 67.15% 67.15%
0.00% 0.00% 0.00% 0.02% 0.02% 0.06% 0.04% 0.05% 0.01% 0.03% 0.05% 0.10%
0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01%
32.81% 32.81% 32.81% 32.80% 32.78% 32.78% 32.80% 32.77% 32.82% 32.81% 32.79% 32.74%
No. of Shareholders 6,2125,8915,9156,1266,3625,9276,0076,97011,24411,29511,32214,270

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls